1. GSK1904529A, an insulin-like growth factor-1 receptor inhibitor, inhibits glioma tumor growth, induces apoptosis and inhibits migration3.
- Author
-
QIANG ZHOU, JUNXIA ZHANG, QINYING CUI, XIAODONG LI, GE GAO, YANFEN WANG, YUPING XU, and XIAOQUN GAO
- Subjects
- *
GLIOMA treatment , *INSULIN-like growth factor receptors , *SOMATOMEDIN C , *APOPTOSIS , *CELL migration , *PHOSPHORYLATION , *PREVENTION ,TUMOR growth prevention - Abstract
Malignant gliomas are the most common type of primary malignancy of the central nervous system, with a poor prognosis. The therapeutic options for malignant gliomas are limited and far from satisfactory, and novel treatment strategies are urgently required to improve the outcome of the disease. Insulin-like growth factor (IGF)/IGF-1 receptor (IGF-1R) signaling pathway regulates cell proliferation, motility and survival. The dysregulation of this signaling pathway has been implicated in the development of malignant gliomas. In the present study, GSK1904529A, a small molecule inhibitor of IGF-1R, suppressed glioma cell viability, induced glioma cell apoptosis and inhibited glioma cell migration in vitro. In addition, GSK1904529A inhibited glioma tumor growth and induced tumor cell apoptosis in vivo. In conclusion, the results of the present study suggested GSK1904529A as a promising agent for the treatment of malignant glioma. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF